Sitagliptin Alleviates Radiation-Induced Kidney and Testis Degeneration in Rats [PDF]
BiomoleculesBackground: Radiation-induced tissue degeneration is the most important side effect of radiotherapy. Sitagliptin with its anti-inflammatory and antioxidant capacity was tested in alleviating the radiation-induced cellular degeneration in kidney and ...
Huseyin Celik +4 more
doaj +2 more sources
Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells [PDF]
Journal for ImmunoTherapy of CancerBackground Dendritic cell (DC)-mediated antigen presentation is essential for the priming and activation of tumor-specific T cells. However, few drugs that specifically manipulate DC functions are available. The identification of drugs targeting DC holds
Zheng Huang +9 more
doaj +2 more sources
MicroRNAs modulated by DPP-4 inhibitor and bedtime NPH insulin therapy in individuals with type 2 diabetes [PDF]
Frontiers in EndocrinologyBackgroundMicroRNAs (miRNAs) and their target genes can elucidate mechanisms of drug action and serve as potential therapeutic biomarkers.MethodsTo evaluate the effects of bedtime NPH insulin and sitagliptin on serum miRNA expression in individuals with ...
Aritania Sousa Santos +3 more
doaj +2 more sources
Sitagliptin, a DPP‐4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial [PDF]
Journal of DiabetesBackground This randomized controlled trial (RCT) was designed to evaluate the effects of sitagliptin on diabetic foot ulcers (DFUs). Methods This was a randomized, open‐label clinical trial.
Wei Gao +5 more
doaj +2 more sources
Sitagliptin ameliorates microbial dysbiosis and enhances gut barrier integrity in streptozotocin-induced type 2 diabetic rats. [PDF]
Front MicrobiolChang Y +5 more
europepmc +3 more sources
Drugs, 2007 Sitagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. This increases active incretin and insulin levels, and decreases glucagon levels and post-glucose-load glucose excursion.
Daniel Drucker +2 more
+5 more sources
The therapeutic effects of berberine plus sitagliptin in a rat model of fatty liver disease [PDF]
Iranian Journal of Basic Medical Sciences, 2021 Objective(s): Fatty liver disease (FLD) is a disorder related to accumulation of excess fat within the hepatocytes. In this study, the effects of Berberine, a natural compound, and Sitagliptin as a DPP-4 inhibitor, were observed in a rat model of FLD ...
Soraya Mehrdoost +3 more
doaj +1 more source
Sitagliptin Mitigates Diabetic Cardiomyopathy Through Oxidative Stress Reduction and Suppression of VEGF and FLT-1 Expression in Rats. [PDF]
BiomoleculesAlqahtani QH +6 more
europepmc +3 more sources
Maternal sitagliptin treatment attenuates offspring glucose metabolism and intestinal proinflammatory cytokines IL-6 and TNF-α expression in male rats [PDF]
PeerJ, 2020 Increasing evidence shows that maternal overnutrition may increase the risk of diabetes in offspring. We hypothesized that maternal sitagliptin intervention may improve glucose intolerance through gut targeting. Female Sprague-Dawley (SD) rats were fed a
Qian Zhang +7 more
doaj +2 more sources
Identification of sitagliptin binding proteins by affinity purification mass spectrometry
Acta Biochimica et Biophysica Sinica, 2022 Type 2 diabetes mellitus (T2DM) is recognized as a serious public health concern with increasing incidence. The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin has been used for the treatment of T2DM worldwide.
Wang Xue-Ning +12 more
doaj +1 more source